The untimely death of patients from metastatic breast carcinoma and other malignant
neoplasms haunts all medical professionals. The tumoricidal potency of doxorubicin …

Myocardial damage may be induced by several categories of drugs. Adriamycin is one of the
most effective chemotherapeutic agents. Unfortunately, it develops a distinctive and life …

Endomyocardial biopsies were examined in 12 patients receiving total doses of Adriamycin
from 90 to 445 mg/M 2. These patients had also received previous mediastinal irradiation …

Eighty Stage IV breast cancer patients treated with Adriamycin (doxorubicin hydrochloride)
in clinical trials were evaluated for cardiotoxicity which was defined as either a significant but …

RESULTS No mortality occurred in the control, 6-wk and 8-wk groups, however, 60% in the
9-wk group and 82% of the 1O-wkgroup died duringthe treatmentperiod. The average body …

Metaiodobenzylguanidine: Evaluation of Its Potential as a Tracer for Monitoring Doxorubicin
Cardiomyopathy Page 1 namycin is one of the most importantcancer che motherapeutic agents …

Adriamycin (doxorubicin) is a valuable cytotoxic agent the administration of which is limited
by the development of a cumulative, dose-related cardiomyopathy (Bristow et al., 1982). It …

MATERIALS AND METHODS Adriamycin powder was supplied from Kyowa Hakko Kogyo
Co., Ltd. Male Wistar rats, weighing 250 ±20 g, were injected with adriamycin (2 mg/kg …

Adriamycin (doxorubicin hydrochloride) is an antineoplastic agent effective against a wide
range of malignant conditions, although cardiac toxicity, especially dose-dependent …

Endomyocardial biopsies and cardiac catheterizations were performed in 55 patients treated
with adriamycin (ADM). Eleven patients underwent serial invasive studies. In addition, most …